Enzymotec   Report issue

For profit Phase 4
Founded: Migdal Hameq Israel (1998)
Status: Acquired by Frutarom Netherlands B.V. (2017)

Organization Overview

First Clinical Trial
2007
NCT00441480
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2015

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Active Ingredients

Drugs in Phase 4 Trials (3)

icosapent ethyl (vascepa) (3 trials)

phytosterol (1 trial)

ptd-l-ser (3 trials)

Drugs in Other Trials (3)

fish oil (Omegavan) (1 trial)

krill oil (1 trial)

vayarin (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Dyslipidemias (Phase 4)

Memory Disorders (Phase 4)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 6
  • # of Trial APIs: 6